13F filing recap · Q2 2026
What did Brave Warrior Advisors buy in Q2 2026?
Reported stock-position changes between this filing and the previous one.
Stock value
$4.59B
Positions
40
Estimated turnover
24.7%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Brave Warrior Advisors opened a position in Arthur J. Gallagher & Co., along with smaller new stakes in S&P Global, Nu Holdings, Texas Instruments, Analog Devices, Visa, and UnitedHealth Group. The firm exited Apollo Global Management, Ares Management, and First American Financial. It substantially trimmed TD Synnex and F&G Annuities & Life, moderately reduced Elevance Health and Millrose Properties, and added to Ryanair Holdings. The firm also sharply increased its HCA Healthcare, Microsoft, and Mastercard positions.